Pall Will Seek To Aid FDA In U.S. Leukocyte Filtration Initiatives
This article was originally published in The Gray Sheet
Executive Summary
Pall Corporation will aid FDA through broad-scale programs in implementing routine leukocyte filtration of the U.S. blood supply, the company says.
You may also be interested in...
Universal Leukocyte Reduction To Double Annual Blood Filtration Market
Universal leukocyte reduction of all blood units used for transfusions in the U.S. would roughly double the market for the blood filters to about $420 mil., annually.
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.